Related Experiment Video
Updated: Mar 30, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Chemosensitization of Prostate Carcinoma Cells with a Receptor-directed Smac Conjugate
Alexander Sturzu, Sumbla Sheikh1, Hartmut Echner
1Department of Neuroradiology University of Tübingen Hoppe-Seyler-Str.3 72076 Tübingen, Germany. sumblafarooq@yahoo.com.
Background:
Second mitochondrial activator of caspase (Smac) is a short mitochondrial peptide. When released from the mitochondria into the cytoplasm, it binds to inhibitor of apoptotic proteins (IAPs) within the cytoplasm and prevents them from inhibiting apoptosis.
Objective:
Delivery of external synthetic Smac peptide into the cytoplasm of malignant cells could greatly improve the efficiency of apoptosis-inducing chemotherapeutic agents.
Method:
In our study different conjugates based on the seven N-terminal amino acids AVPIAQK of Smac (SmacN7) were produced to obtain a cytoplasm-directed Smac variant. SmacN7 and a point mutant (AVPKAQK) were coupled either to rhodamine alone or to both rhodamine and undecylic aldehyde, which is an antagonist of the Lily-of-the-valley fragrance receptor. The fifth conjugate consisted of rhodamine coupled only to undecylic aldehyde, without SmacN7. The uptake of these five conjugates into three different human cell lines was characterized and quantified by confocal laser scanning microscopy and flow cytometry. A caspase apoptosis assay was performed for cells incubated with the five different conjugates after induction of apoptosis.
Results:
The coupling of undecylic aldehyde to SmacN7 increased the cellular uptake of the correct and mutant conjugates.
Conclusion:
Caspase 3/7 apoptosis tests after induction of apoptosis with staurosporine or UV irradiation showed that the coupling of SmacN7 with undecylic aldehyde resulted in a greatly increased adjuvant pro-apoptotic effect compared to the separate components and a mutant SmacN7 peptide sequence in the LNCaP prostate carcinoma cells compared to the benign prostate hyperplasia (BPH) cells and the human embryonal kidney (HEK) cells.
Insights
Synthetic Smac peptide variants conjugated with undecylic aldehyde enhanced cellular uptake and apoptosis. This SmacN7-aldehyde conjugate significantly boosted pro-apoptotic effects in cancer cells.
Area of Science:
- Biochemistry
- Cell Biology
- Molecular Medicine
Background:
- Second mitochondrial activator of caspase (Smac) is a peptide that promotes apoptosis by inhibiting IAPs.
- Cytoplasmic release of Smac is crucial for its function in blocking apoptosis.
- Targeting Smac delivery to malignant cells offers a strategy to enhance cancer therapy.
Purpose of the Study:
- To develop cytoplasm-directed Smac variants for improved apoptosis induction.
- To investigate the effect of conjugating SmacN7 with undecylic aldehyde on cellular uptake and pro-apoptotic activity.
- To compare the efficacy of SmacN7 conjugates in different human cell lines.
Main Methods:
- Synthesis of SmacN7 conjugates with rhodamine and/or undecylic aldehyde.
- Quantification of conjugate uptake in LNCaP, BPH, and HEK cells using microscopy and flow cytometry.
- Assessment of apoptosis induction via caspase assays after treatment with staurosporine or UV irradiation.
Main Results:
- Conjugation of undecylic aldehyde to SmacN7 significantly increased cellular uptake of the peptide.
- The SmacN7-undecylic aldehyde conjugate demonstrated a potent adjuvant pro-apoptotic effect.
- Enhanced apoptosis was observed in LNCaP prostate carcinoma cells compared to BPH and HEK cells.
Conclusions:
- The SmacN7-undecylic aldehyde conjugate is an effective strategy for enhancing apoptosis in cancer cells.
- Undecylic aldehyde conjugation improves Smac peptide delivery and pro-apoptotic efficacy.
- This approach holds promise for improving the effectiveness of apoptosis-inducing chemotherapeutic agents.
More Related Videos
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...